Press Release
FormBlends Launches the Most Comprehensive GLP-1 and Peptide Intelligence Platform on the Internet, Featuring 7,282 Provider Profiles and 100 Clinical Research Reports
San Francisco, CA, April 9th, 2026 – FormBlends, a health technology platform focused on GLP-1 weight loss results and weight management provider directory listings, today announced the completion of a major platform expansion that positions it as the most comprehensive consumer intelligence resource for prescription weight management medications in the United States. The platform now features 7,282 individually profiled provider listings across all 50 states, 100 physician-reviewed clinical research reports, 17 interactive health tools, and a clinical education library covering every major GLP-1 and peptide therapy on the market.

As the $45 billion GLP-1 market accelerates toward $122 billion by 2030, FormBlends is building the definitive consumer resource for evidence-based medication information, provider transparency, and clinical education.
FormBlends: Building the most comprehensive GLP-1 and peptide intelligence platform on the internet
The announcement comes as the global GLP-1 receptor agonist market reaches $45.3 billion in 2025, projected to hit $122.3 billion by 2030.
Goldman Sachs forecasts the anti-obesity drug market at $95 billion by 2030. J.P. Morgan projects the global incretin market at $200 billion by the same year. Morgan Stanley estimates $77 billion.
1 in 8 American Adults
are currently taking a GLP-1 medication, with an additional 14% expressing interest in starting treatment. Monthly prescriptions for GLP-1 receptor agonists have grown from 700,000 to 2.6 million since 2021.
An Information Crisis in the Fastest-Growing Drug Category
The explosive growth of GLP-1 receptor agonist therapies has created an equally explosive information gap. The National Consumers League documented a 1,200% increase in “violative or problematic” GLP-1-related advertising between 2022 and 2024. Separately, the National Association of Boards of Pharmacy found that approximately 95% of websites offering prescription-only medications online operate outside of legal requirements, with 96% not requiring a valid prescription.
Harvard Medical School researchers have flagged social media as a primary vector for GLP-1 misinformation, with platforms like TikTok rampant with false claims about supplements and foods that supposedly replicate the effects of prescription medications. The FDA has issued multiple warnings about fraudulent products with false labeling entering the market.
“Patients are navigating an information environment where marketing is frequently disguised as medical advice,” said a FormBlends spokesperson. “The gap between what consumers need to know and what they can reliably find online is widening every month. We built this platform to close that gap with physician-reviewed, evidence-based clinical content.”
“We are not building a company that happens to have health content. We are building the most trusted clinical resource on the internet for GLP-1 and peptide therapy information, backed by peer-reviewed research and transparent provider data.”
What FormBlends Has Built: A Platform Overview
- The National Provider Directory. FormBlends now maintains 7,282 individually profiled weight management clinic listings across all 50 states, each featuring verified ratings, treatment offerings, pricing transparency data, patient review analysis, and an editorially written assessment. Unlike aggregator sites that scrape listings without context, every FormBlends profile includes editorial content reviewed by the platform’s medical team, honest advantages and limitations, and transparent cost comparison information. Provider data is sourced from the Yelp Fusion API and verified quarterly.
- Clinical Research Library. The platform’s research section houses 100 physician-reviewed reports covering GLP-1 receptor agonists, peptide therapies, and weight management science. Each report cites peer-reviewed sources from journals including the New England Journal of Medicine, JAMA, The Lancet, and Nature Medicine. FormBlends’ ambition is to function as the most complete reference library for GLP-1 and peptide clinical data on the internet, organized and explained for patients rather than clinicians.
- Interactive Health Tools. FormBlends offers 17 free clinical tools including a BMI calculator, drug interaction checker, insurance coverage checker, dosing schedule planner, peptide dosage calculator, and weight loss timeline estimator. These tools are designed to help patients prepare for conversations with their physicians, not replace medical consultation.
- Educational Article Library. The platform’s clinical education library includes comprehensive guides organized by drug class and therapeutic category. Article hubs cover GLP-1 receptor agonists, peptide therapy, medication comparisons, side effect profiles, dosing protocols, and cost analyses. Every article is medically reviewed and updated quarterly with current clinical data. All clinical claims cite peer-reviewed sources.
The Clinical Evidence: Why GLP-1 Medications Are Reshaping Medicine
The scale of FormBlends’ investment in clinical education reflects the extraordinary scope of what published research shows GLP-1 receptor agonists are capable of. These medications have demonstrated benefits extending well beyond weight management into cardiovascular disease, kidney disease, and metabolic health, representing what many researchers describe as the most significant pharmacological development in endocrinology in decades.
| Clinical Trial | Published Finding | Source |
| STEP 1-4 | 14.9%-17.4% mean body weight loss at 68 weeks; 69-79% of patients achieved clinically meaningful weight reduction | NEJM, 2021 |
| STEP 5 (Long-term) | 16.7% sustained weight reduction maintained at 104 weeks vs. 0.6% with placebo | Nature Medicine, 2022 |
| SURMOUNT-1 | 22.5% weight reduction at highest dose; 63% of participants achieved 20% or greater reduction | NEJM, 2022 |
| SURMOUNT-5 (Head-to-Head) | Tirzepatide 20.2% vs. semaglutide 13.7% weight reduction at 72 weeks | Applied Clinical Trials, 2025 |
| SELECT (Cardiovascular) | 20% reduction in major adverse cardiovascular events across 17,604 patients (HR 0.80) | NEJM, 2023 |
| FLOW (Kidney) | 24% reduction in composite kidney endpoint; trial stopped early due to efficacy | ADA, 2024 |
FormBlends’ research library provides detailed breakdowns of each of these trials, including a comprehensive semaglutide vs tirzepatide comparison, all translated from clinical language into patient-accessible explanations. The platform’s goal is to make published clinical data as accessible as possible, so patients can have informed conversations with their physicians about whether these therapies may be appropriate for their individual circumstances.
A $1.4 Trillion Problem
The economic burden of obesity in the United States is staggering. The Milken Institute and the GWU STOP Obesity Alliance estimate the total economic impact at $1.4 trillion annually when accounting for direct medical expenses and lost productivity.
Adults with obesity incur an average of $2,505 more in annual medical costs than normal-weight adults, with costs escalating to 233.6% higher for individuals with Class 3 obesity. US prescription drug spending hit $805.9 billion in 2024, up 10.2% year-over-year, with weight management medications accounting for 46.8% of the total increase.
Total US spending on GLP-1 receptor agonists grew over 500% from $13.7 billion in 2018 to $71.7 billion in 2023, according to a study published in JAMA Network Open.
$71.7 Billion
Total US GLP-1 receptor agonist spending in 2023, up from $13.7 billion in 2018. Weight management medications drove 46.8% of all US prescription drug spending growth in 2024.
Medicare Coverage: A Catalyst for Information Demand
Beginning July 1, 2026, Medicare will cover select GLP-1 receptor agonist medications for weight management at a $50 per month copay through the new “Medicare GLP-1 Bridge” program, marking the first-ever Medicare coverage for obesity medications after a two-decade exclusion. The CMS BALANCE Model, launching January 2027 for Medicare Part D, is projected to further expand access.
Goldman Sachs projects 15 million US adults will be on anti-obesity medications by 2030, representing 13% of the adult population excluding those with diabetes. J.P. Morgan’s estimate is higher: 25 million Americans by the same year.
“Medicare coverage will bring tens of millions of new patients into this category for the first time,” said a FormBlends spokesperson. “These patients will need reliable, physician-reviewed information to make informed decisions. That is exactly what our clinical resources and research library are designed to provide. We want to be the place physicians recommend their patients go to learn.”
The Peptide Frontier: Education Beyond GLP-1
FormBlends’ platform extends beyond GLP-1 receptor agonists into the broader peptide therapy landscape, which reached $140.86 billion globally in 2025 and is projected to grow to $260.25 billion by 2030 at a 10.77% CAGR.
The platform’s peptide education resources, dosage calculators, and reconstitution reference tools serve a growing consumer segment seeking evidence-based information about therapies gaining attention in longevity and regenerative medicine research. The platform’s retatrutide research hub covers next-generation triple-agonist GLP-1 therapies currently in late-stage clinical trials.
The Search for Answers: Consumer Behavior Signals Demand for Better Resources
Consumer search behavior reflects the intensity of demand for reliable GLP-1 information. The term “GLP-1” now averages over 3 million monthly Google searches, having surpassed “Ozempic” in search volume by early 2025 as consumers shift from brand-name awareness to drug-class research.
A longitudinal analysis published in PMC found that prescription volume and search volume for GLP-1 medications are correlated at r = 0.97, one of the highest correlation coefficients ever recorded between prescription drug utilization and online search behavior. This suggests that patients are actively researching these medications before and during treatment.
This behavioral shift signals a more sophisticated patient population, one that is no longer searching for a brand name from a television commercial but actively comparing clinical evidence, evaluating providers, and assessing costs before making treatment decisions. FormBlends’ provider comparison tools, head-to-head treatment analyses, and ranked provider guides are built specifically for this informed patient.
A New Face of Wellness
FormBlends’ thesis is that the GLP-1 era represents a fundamental shift in how Americans relate to their own health. For the first time, millions of people who were told that weight management was purely a matter of willpower have access to medications that address underlying biological mechanisms, medications backed by the largest, most rigorous clinical trial programs in modern endocrinology.
The company’s content philosophy reflects this shift. FormBlends does not position itself as a marketing platform. It provides clinical information, transparent provider data, and educational resources that allow patients to make decisions grounded in evidence rather than advertising. Every page on the platform, from the side effects guides to the provider directory to the health assessment, is reviewed by licensed clinicians and updated with current published data.
“For decades, the wellness industry sold aspiration. We are building something different: a platform that provides clarity. Patients deserve to know what these medications do, what the published clinical evidence shows, and where to find a qualified provider. If we do that well, the rest takes care of itself.”
“The consumer searching for GLP-1 information in 2026 is fundamentally different from the consumer who first typed ‘Ozempic’ into Google in 2023,” said a FormBlends spokesperson. “They are researching drug classes, reading published trial data, and comparing provider credentials before scheduling consultations. We built this entire platform for that patient.”
By the Numbers: FormBlends Platform as of April 2026
| Platform Metric | Value |
| Provider profiles maintained | 7,282 across all 50 states + D.C. |
| Clinical research reports | 100 physician-reviewed |
| Interactive health tools | 17 (free, no account required) |
| Educational articles | 200+ medically reviewed guides |
| Drug classes covered | GLP-1 receptor agonists, peptides, TRT |
| FAQs answered | 72,820+ across directory and articles |
| Medical review process | All content reviewed by licensed clinicians |
| Content update cycle | Quarterly with latest published clinical data |
| Provider data source | Yelp Fusion API, verified quarterly |
| Health assessment | Free 2-minute online assessment |
Availability
The FormBlends platform is available now at formblends.com. All educational content, research reports, interactive tools, and provider directory listings are free to access. Patients interested in exploring whether physician-supervised treatment may be appropriate for their circumstances can begin with a free health assessment.
About FormBlends
FormBlends is a health technology platform focused on GLP-1 receptor agonist education, peptide therapy research, and clinical health information. The platform combines the largest independently maintained weight management provider directory in the United States with interactive health tools, a peer-reviewed clinical research library, and physician-supervised telehealth consultations. All medical content is reviewed by licensed clinicians. Learn more at formblends.com.
Important Disclosures: This press release is for informational purposes only and does not constitute medical advice. GLP-1 receptor agonist medications are prescription treatments that require evaluation by a licensed healthcare provider. Clinical trial results cited in this release refer to published, peer-reviewed studies of FDA-approved branded medications and may not be representative of outcomes with any other products. Individual results vary. Always consult a qualified healthcare professional before starting any prescription treatment. The FormBlends provider directory is an informational resource; inclusion does not constitute endorsement. Provider data is sourced from publicly available information and verified quarterly.
Media Contact
FormBlends Communications
Team@formblends.com
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Brian Baldari on the Difference Between a Mentor and a Sponsor, and Why It Decides Promotions
-
ResilExec® Coaching founder Brian Baldari, Pharm.D., MBA, on why senior leaders who have plenty of advice and no advocacy stall at the same level for years.
BRICK, N.J., Oct 03, 2026, ZEX PR WIRE — Most senior professionals have someone they go to for advice. Far fewer have someone who argues for them in a room they are not in. According to Brian Baldari, Pharm.D., MBA, founder of ResilExec® Coaching, that distinction accounts for a large share of stalled advancement among otherwise strong performers.
Baldari spent 24 years inside pharmaceutical, healthcare, and enterprise leadership organizations. He held five successive Director-level roles, moved from Director to Vice President and Senior General Manager in 18 months, and led the commercial launch of 14 brands. He now works with Associate Directors, Directors, Senior Directors, Executive Directors, and Vice Presidents inside pharmaceutical, healthcare, and enterprise IT organizations.
“A mentor talks to you. A sponsor talks about you,” Baldari says. “One of those changes your calendar. The other changes your title.”
Advice Is Not Advocacy
Mentorship is widely available and widely encouraged. Many organizations run formal programs for it. A mentor offers perspective, context, and guidance, and that guidance has real value early in a career when the primary gap is knowledge.
Sponsorship operates differently. A sponsor spends their own credibility on someone else. They put a name forward on a succession slate, defend a candidate during calibration, and accept the consequences if the bet does not pay off. That is a materially different act, and it is not something an organization can mandate.
“Leaders collect mentors because mentors are easy to ask for,” Baldari says. “Nobody feels awkward requesting advice. Asking someone to spend their reputation on you is a different conversation, and most people never have it.”
Where the Gap Shows Up
The gap becomes visible at the point where advancement decisions are made collectively. Calibration sessions and succession discussions involve people across multiple functions, many of whom have no direct experience of a given candidate’s work. In those rooms, a candidate is represented by whoever chooses to speak.
“If nobody in that room can describe what you do at enterprise scale, you are not in the conversation, regardless of your review,” Baldari says. “The decision is not made on the strength of your record. It is made on the strength of the description someone else gives of it.”
Baldari notes that this is where strong performers are most often surprised. Their performance ratings are high, their manager is supportive, and the outcome still does not change, because the people who influenced the decision were never engaged.
Sponsorship as a Variable
Sponsorship is one of five variables in Baldari’s Promotion Math
framework, alongside Performance, Visibility, Narrative, and Timing. In his assessment, strong performers optimize the first variable and leave the remaining four unattended, then attribute the result to politics.
“Performance gets you noticed. Positioning gets you promoted,” Baldari says. “Sponsorship is the variable people find hardest to work on, because it requires asking for something rather than producing something.”
What Changes the Outcome
Baldari advises leaders to identify the specific individuals who will participate in the decisions that affect them, then assess honestly whether those individuals could describe their contribution without prompting. In most cases the answer is no, and that is the actionable finding.
From there the work is practical rather than social. It involves delivering value to those individuals rather than checking in with them, framing results at enterprise level rather than functional level, and showing up in forums where that work is visible to people beyond a direct reporting line.
“You do not recruit a sponsor by asking them to be one,” Baldari says. “You give them something worth putting their name next to, and you make sure they understand what it was.”
About Brian Baldari
Brian Baldari, Pharm.D., MBA, based in Brick, New Jersey, is the founder of ResilExec® Coaching and Resilient Performance Group LLC. He spent 24 years inside pharmaceutical, healthcare, and enterprise leadership organizations, held five successive Director-level roles, and advanced from Director to Vice President and Senior General Manager in 18 months. He led the commercial launch of 14 brands across rare and chronic disease categories, led an organization of more than 250 people, and has mentored more than 50 leaders across three continents. Through ResilExec Coaching, he helps Associate Directors, Directors, Senior Directors, Executive Directors, and Vice Presidents accelerate career growth through personalized executive coaching, leadership development, and strategic career positioning.
Media Contact
Resilient Performance Group LLC
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Timothy Caraboolad Publishes a Buyer’s Checklist for New-Build Condos in South Florida
-
Real estate developer Timothy Caraboolad is releasing a set of questions first-time buyers should ask before putting money down on a new-build apartment in South Florida.
A market full of new buildings, and a lot of first-time buyers
Florida, USA, Oct 03, 2026, ZEX PR WIRE — South Florida has no shortage of new construction. Buildings go up fast, sales offices open before the concrete cures, and renderings promise more than any buyer can verify in a single walkthrough.
Timothy Caraboolad, a real estate developer and designer based in Palm Beach, Florida, has spent years on the other side of that process, building high-end custom homes through his firm Lad Design. He says the buyers who end up happiest are the ones who ask harder questions earlier, not the ones who fall for the best rendering.
“A sales gallery is designed to sell you a feeling,” he says. “Your job as a buyer is to slow that down and ask what you’re actually getting for the price.”
What to check before signing anything
Caraboolad points first-time buyers toward a few areas that matter more than finishes.
Construction quality behind the walls. Countertops and cabinetry are easy to judge. What is inside the walls is not. Caraboolad suggests asking who the general contractor is, how long they have built in the area, and whether the building uses concrete or wood-frame construction, since that affects sound, insurance, and long-term durability in a hurricane-prone region.
HOA fees and what they actually cover. New buildings often advertise low fees at launch that rise once amenities open and reserves get funded. “Ask for the projected budget once the building is fully occupied, not just the introductory number,” Caraboolad says. He recommends buyers ask specifically what percentage of the fee goes into reserves, since that determines whether the building can pay for a roof or a seawall repair without a special assessment.
Storm readiness. In South Florida, this is not optional. Buyers should ask about impact windows, generator backup for elevators and common areas, and flood elevation. Caraboolad says a building’s flood zone designation should be requested in writing, not estimated by a sales agent.
Parking and storage, spelled out. Some buildings sell parking as a deeded asset. Others assign it and can reassign it later. Caraboolad says this distinction matters more than most buyers realize until after closing.
Developer track record. A new building has no resale history to check. Caraboolad suggests buyers look at other projects the same developer has completed, not just renderings of the one being sold, and ask how those buildings have held up.
Timing the purchase
For pre-construction units, Caraboolad says the biggest risk is not price, it is timeline. Delays are common, and buyers should understand what happens to their deposit if the closing date slips.
“Get the outside date for completion in writing,” he says. “And ask what your options are if that date passes.”
He also encourages buyers to walk a finished unit in the same building, or a comparable one from the same developer, before relying on a model unit that may use upgraded finishes not included in the base price.
Why this matters for first-time buyers specifically
Caraboolad says first-time buyers face a particular disadvantage: they often do not know which questions are normal to ask, so they accept vague answers.
“An experienced buyer will push back on a soft answer about HOA reserves or insurance history,” he says. “A first-time buyer might just assume that’s how it works. It isn’t. You’re allowed to ask for documentation before you commit.”
His broader point is that a new building can be a strong investment in South Florida, but only when the buyer treats the sales process the same way a developer would: checking budgets, checking materials, and checking the people building it, before checking the view.
About Timothy Caraboolad
Timothy Caraboolad is an entrepreneur, real estate developer, and designer based in Palm Beach, Florida. He is the founder of Lad Design, a South Florida firm building high-end custom homes, and previously founded Arc Design, a luxury residential development and design firm in the Boston area. He holds a Bachelor’s Degree in International Business from Rollins College.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Jermaine Gassaway: A checklist for parents choosing school leadership
-
Jermaine Gassaway, a superintendent and public education advocate, outlines what parents should look for in school and district leaders before enrolling their children.
Why leadership is the first thing to check
North Carolina, USA, Oct 03, 2026, ZEX PR WIRE — Parents often start a school search by looking at test scores or building tours. Jermaine Gassaway says that misses the bigger question: who is running the school, and how do they lead.
“A building can look great and still have weak instruction,” Gassaway says. “The leader sets the tone for everything else. If you skip that part of the search, you’re missing the most important piece.”
Gassaway has worked as a teacher, a principal, and a superintendent. That range gives him a view of leadership from more than one seat, and he says the questions parents ask should change depending on what they can actually observe.
What to ask before you tour the building
Gassaway suggests parents start with a short list of questions for any principal or superintendent they meet.
How do you measure growth, not just scores. A single test score tells a parent almost nothing about whether their child is improving. Gassaway says leaders who can talk about growth over time, not just a snapshot, are paying attention to the right thing.
How often are you in classrooms. A principal’s visibility in classrooms is a signal of how closely they track teaching day to day. Gassaway says parents should ask directly how often the leader observes instruction and gives feedback to teachers.
What happens when a student falls behind. Every school has students who struggle. Gassaway says the real question is whether there is a clear plan, with specific support, for those students, or whether it is left to chance.
How do you support new teachers. Turnover affects children directly. Gassaway says parents should ask how new teachers are coached in their first year, since that shapes whether a child gets a stable classroom experience.
Red flags parents should not ignore
Gassaway points to a few signs that should raise questions, even if the rest of a school visit goes well.
A leader who cannot describe how they use data. If a principal talks only in generalities about student progress, Gassaway says that is worth a follow-up question.
A staff that seems unsettled or unclear on expectations. Gassaway says parents can pick up on this just from talking to teachers or reading how a school communicates with families.
No clear answer on discipline or support plans. Parents should expect a straight answer on how the school handles behavior and academic struggles, not a vague reassurance.
What good leadership sounds like
Gassaway says strong school leaders tend to talk in specifics. They can describe how a reading program works, not just that the school “cares about literacy.” They know their staff by name and can speak to strengths and gaps on their team. They treat parent questions as normal, not as a challenge to be managed.
“You can tell a lot from how a leader answers a hard question,” Gassaway says. “Do they get defensive, or do they give you a real answer. That tells you how they’ll treat you once your child is enrolled.”
A short list parents can bring to a school visit
Gassaway recommends parents keep it simple: three or four questions, asked directly, with room to follow up.
-
How do you track whether students are growing, not just passing.
-
How often are you in classrooms, and what do you look for.
-
What is your plan when a student is behind grade level.
-
How do you support teachers who are new to the school.
He says the answers matter less for their polish and more for their specificity. “A leader who knows their school will have real answers,” Gassaway says. “A leader who doesn’t will talk around it.”
About Jermaine Gassaway
Jermaine Gassaway is a superintendent based in Charlotte, North Carolina. He is a former teacher and school principal, and the author of “Unopened Books: Multiplying the 2%” and “When You Arrive: A Children’s Book About Racism.” He is a graduate of Johnson C. Smith University and has worked in public education for more than a decade.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
-
Press Release1 week ago
Just Keepers Spotlights Keeper iD’s New Range of Junior Goalie Gloves
-
Press Release1 week ago
Results Digital Expands Website Design Offerings for General Contractors in Houston TX
-
Press Release7 days ago
Piya Saliba Releases Free Community Connection Checklist to Help People Build Stronger Relationships
-
Press Release1 week ago
Whimsical Halloween Wardrobe Ready: Arshiner Kids’ Outfits Light Up the Trick-or-Treat Adventure
-
Press Release6 days ago
New Experiences in Shanghai for Mid-Autumn Festival and National Day! The 2026 International Audio-Visual Arts Carnival Unveils a “Technology + Culture” Audio-Visual Feast
-
Press Release7 days ago
Gary Bassett Shares Lessons From 45 Years Across Finance and Technology
-
Press Release1 week ago
Painted Brick Digital Named Among Expertise.com’s Top 8 Legal Marketing Companies in Scottsdale
-
Press Release7 days ago
Nivia Fontanez Highlights the Often-Overlooked Role of Radiology Technologists in Patient Care
